Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/8052
Title: | Does spironolactone have a dose-dependent effect on left ventricular remodeling in patients with preserved left ventricular function after an acute myocardial infarction? | Authors: | Vatankulu, M.A. Bacaksiz, A. Sonmez, O. Alihanoglu, Y. Koc, F. Demir, K. Gul, E.E. |
Keywords: | Aldosterone Myocardial infarction Preserved ejection fraction Remodeling Spironolactone acetylsalicylic acid bisoprolol carvedilol fosinopril metoprolol perindopril ramipril spironolactone valsartan acute heart infarction adult article controlled study echocardiography female follow up gynecomastia heart left ventricle ejection fraction heart left ventricle enddiastolic volume heart left ventricle endsystolic volume heart left ventricle function heart performance heart ventricle remodeling human hyperkalemia hypotension major clinical study male priority journal randomized controlled trial ST segment elevation myocardial infarction Adult Aged Analysis of Variance Chi-Square Distribution Dose-Response Relationship, Drug Echocardiography, Doppler Female Humans Male Middle Aged Mineralocorticoid Receptor Antagonists Myocardial Contraction Myocardial Infarction Prospective Studies Stroke Volume Time Factors Treatment Outcome Turkey Ventricular Function, Left Ventricular Remodeling |
Abstract: | Aims: The aim of this study was to investigate the effects of spironolactone on left ventricular (LV) remodeling in patients with preserved LV function following acute myocardial infarction (AMI). Methods and Results: Successfully revascularized patients (n = 186) with acute ST elevation MI (STEMI) were included in the study. Patients were randomly divided into three groups, each of which was administered a different dose of spironolactone (12.5, 25 mg, or none). Echocardiography was performed within the first 3 days and at 6 months after MI. Echocardiography control was performed on 160 patients at a 6-month follow-up. The median left ventricular ejection fraction (LVEF) increased significantly in all groups, but no significant difference was observed between groups (P = 0.13). At the end of the sixth month, the myocardial performance index (MPI) had improved in each of the three groups, but no significant difference was found between groups (F = 2.00, P = 0.15). The mean LV peak systolic velocities (Sm) increased only in the control group during the follow-up period, but there is no significant difference between groups (F = 1.79, P = 0.18). The left ventricular end-systolic volume index (LVESVI) and the left ventricular end-diastolic volume index (LVEDVI) did not change significantly compared with the basal values between groups (F = 0.05, P = 0.81 and F = 1.03, P = 0.31, respectively). Conclusion: In conclusion, spironolactone dosages of up to 25 mg do not augment optimal medical treatment for LV remodeling in patients with preserved cardiac functions after AMI. © 2012 John Wiley & Sons Ltd. | URI: | https://hdl.handle.net/11499/8052 https://doi.org/10.1111/1755-5922.12006 |
ISSN: | 1755-5914 |
Appears in Collections: | PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection Tıp Fakültesi Koleksiyonu WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection |
Files in This Item:
File | Size | Format | |
---|---|---|---|
1755-5922.12006.pdf | 105.2 kB | Adobe PDF | View/Open |
CORE Recommender
SCOPUSTM
Citations
12
checked on Nov 16, 2024
WEB OF SCIENCETM
Citations
11
checked on Nov 21, 2024
Page view(s)
28
checked on Aug 24, 2024
Download(s)
26
checked on Aug 24, 2024
Google ScholarTM
Check
Altmetric
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.